| Literature DB >> 28572599 |
Monica Varano1, Pierluigi Iacono1, Massimiliano M Tedeschi1, Claudio Letizia2, Mario Curione3, Claudio Savoriti3, Erika Baiocco3, Laura Zinnamosca2, Cristiano Marinelli2, Barbara Boccassini1, Mariacristina Parravano4.
Abstract
Case-control observational study to evaluate the microvascular and macrovascular changes in patients with hypertension secondary to primary aldosteronism (PA), essential hypertension (EH) and healthy subjects. Measurements of arterial stiffness including augmentation index (AIx) and pulse wave velocity (PWV) were assessed using a TensioClinic arteriograph system. Retinal microcirculation was imaged by a Retinal Vessel Analyzer (RVA) and a non-midriatic camera (Topcon-TRC-NV2000). IMEDOS software analyzed the retinal artery diameter (RAD), retinal vein diameters (RVD) and arteriole-to-venule ratio (AVR) of the vessels coming off the optic disc. Thirty, 39 and 35 patients were included in the PA, EH and control group, respectively. The PA group showed higher PWV values compared only with the control group. The mean brachial and aortic AIx values did not show significant difference between groups. In the PA group, the mean RVD and AVR values were significantly lower than in the EH and control groups, whereas the parameters did not differ between the EH and control groups. In conclusion, AVR appears significantly modified in the PA group compared with the EH group and could represent an early and more reliable indicator of microvascular remodeling.Entities:
Mesh:
Year: 2017 PMID: 28572599 PMCID: PMC5453943 DOI: 10.1038/s41598-017-02622-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Retinal microvascular and systemic macrovascular assessment in hypertension secondary to primary aldosteronism.
| Essential Hypertension (EH) (N 39) | Primary Aldosteronism (PA) (N 30) | Control group (N 35) | F ratio (p value, ANOVA statistic)/Chi-square test (p:value) | |
|---|---|---|---|---|
| Age (years) | 55.8 ± 9.5 | 54.6 ± 11,6 | 53.1 ± 6,9 | 0,816 (p:0.44) |
| Gender (F/M) | 23/16 | 17/13 | 21/14 | 0.07 (p:0.96) |
| Body Mass Index (kg.m−2) | 25.6 ± 3.4 (p: <0.05 vs control) (p:ns vs PA) | 26.2 ± 4.32 (p: <0.05 vs control) | 23.4 ± 2.5 | 5.86 (p:0.004) |
| Mean time of known duration of hypertension (years) | 2.8 ± 2.2 (p: 0.56 vs PA, t-test) | 3.1 ± 2.1 | ||
| Smokers | 8/39 (20%) | 4/30 (13.3%) | 5/35 (14%) | 0.803 (p:0.66) |
| Medications | ||||
|
| 8.41 (p:0.13) | |||
| ACE-I use, | 8 | 5 | ||
| ARB use, | 12 | 9 | ||
| Anti-ALDO | 1 | 9 | ||
| CCB use, | 13 | 16 | ||
| Diuretic use | 16 | 11 | ||
| β-Blocker use | 7 | 7 | ||
|
| 2 | 2 | ||
| SBP clin (mmHg)* | 132.2 ± 13.1 (p: <0.05 vs control) (p:ns vs PA) | 132.2 ± 13 (p: <0.05 vs control) | 120.6 ± 10 | 10.24 (p:<0.001) |
| DBP clin (mmHg)† | 81.5 ± 8.7 (p: <0.05 vs control) (p:ns vs PA) | 83 ± 8.4 (p: <0.05 vs control) | 75.4 ± 8.4 | 7.42 (p:0.001) |
| ABPM-SBP (mmHg)‡ | 129.5 ± 11.1 (p: <0.05 vs control) (p:ns vs PA) | 134.4 ± 17 (p: <0.05 vs control) | 117.5 ± 9.6 | 19.55 (p:<0.001) |
| ABPM-DBP (mmHg) | 79.1 ± 6.3 (p: <0.05 vs control) (p:ns vs PA) | 81.7 ± 10.8 (p: <0.05 vs control) | 71.7 ± 9.4 | 15.74 (p:<0.001) |
| ABPM-HR (bpm)§ | 68.8 ± 9.0 | 70.3 ± 10.1 | 68,7 ± 8,1 | 0.29 (p:0.74) |
| ABPM-MAP (mean arterial pressure)|| (mmHg) | 97.3 ± 8.2 (p: <0.05 vs control) (p:ns vs PA) | 99.3 ± 12.5 (p: <0.05 vs control) | 89.7 ± 9.3 | 8.51 (p:<0.001) |
| ABPM-PP (pulse pressure) (mmHg)# | 49.9 ± 8.3 (p: <0.05 vs control) (p:ns vs PA) | 52.7 ± 9.1 (p: <0.05 vs control) | 45.5 ± 7.8 | 6.50 (p:0.002) |
| ABP (mmHg) | 125.4 ± 11.8 (p: <0.05 vs control) (p:ns vs PA) | 128.9 ± 17.4 (p: <0.05 vs control) | 116 ± 12 | 6.98 (p:0.001) |
| Glycemia (mg/dL) | 94 ± 18 (p:ns vs PA) (p: ns vs control) | 92 ± 13 (p: ns vs control) | 90 ± 10 | 0.33 (p:0.70) |
| Serum potassium (mEq/dL) | 4.27 ± 0.37 (p:ns vs PA) (p: ns vs control) | 3.99 ± 0.68 (p: ns vs control) | 4.21 ± 0.42 | 0.97 (p:0.43) |
| Serum Creatinine (mg/dL) | 0.86 ± 0.15 (p:0.05 vs PA) (p: ns vs control) | 1 ± 0.19 (p: <0.05 vs control) | 0.88 ± 0.16 | 2.34 (p:0.03) |
| Plasma aldosterone (PAC) (ng/dl) | 104 ± 60 (p: <0.05 vs PA) (p: 0.ns vs control) | 426 ± 422 (p: <0.05 vs control) | 85 ± 32 | 8.77 (p:0.001) |
| PAC/PRA (plasma renin activity) ratio (ng/dl:ng/ml/h) | 17.6 ± 15 (p: <0.05 vs PA) (p: 0.ns vs control) | 84.3 ± 79 (p: <0.05 vs control) | 6.6 ± 2.1 | 10.21 (p:0.001) |
Demographic characteristics, clinical data and laboratory testing of the study groups. *Systolic Blood Pressure Clinostatism (SBP clin), †Diastolic Blood Pressure Clinostatism (DBP clin), ‡ambulatory blood pressure monitoring (ABPM), §Heart Rate (HR), ||Mean Arterial Pressure (MAP), #Pulse Pressure (PP), Aortic Blood Pressure (ABP). Medications: ARB: angiotensin receptor blocker. ACE-I: ACE inhibitor; CCB: calcium channel blocker, ANTI-ALDO: anti aldosteronic drugs.
Retinal microvascular and systemic macrovascular assessment in hypertension secondary to primary aldosteronism. Arterial stiffness parameters and retinal microvascular characteristics.
| Essential Hypertension (EH) (39) Mean ± SD | Primary Aldosteronism (PA) (30) Mean ± SD | Control group (35) Mean ± SD | F ratio (p value, ANOVA statistic) | |
|---|---|---|---|---|
| Brachial Aix (%) | −21.9 ± 29.1 (EH vs PA: p:0.82) (EH vs control: p:0.81) | −23.4 ± 26,6 (PA vs control: 0.64) | −20.4 ± 25 | 0.0997 (p:0.905) |
| Aortic AIx (%) | 26.9 ± 16.4 (EH vs PA: p:0.76) (EH vs control: p:0.73) | 25.8 ± 13.5 (PA vs control: 1.00) | 25.8 ± 11.7 | 0.0840 (p:0920) |
| PWV (m/s) | 8.7 ± 2.1 (EH vs PA: p:0.30) (EH vs control: p:0.09) | 9.2 ± 1.9 (PA vs control: 0.01) | 7.7 ± 2.7 | 3.847 (p:0.024) |
| Retinal artery Diameter (µm) | 103.6 ± 11.2 (EH vs PA: p:0.12) (EH vs control: p:0.47) | 98.7 ± 14.2 (PA vs control: 0.06) | 106.3 ± 16.7 | 2.376 (p:0.09) |
| Retinal Vein Diameter (µm) | 134.2 ± 15.9 (EH vs PA: p:0.01) (EH vs control: p:0.96) | 125.2 ± 14.6 (PA vs control: 0.04) | 134.0 ± 19.1 | 3.031 (p: 0.049) |
| AVR (index) | 0.84 ± 0.06 (EH vs PA: p:0.02) (EH vs control: p:0.19) | 0.802 ± 0.07 (PA vs control: 0.001) | 0.86 ± 0.07 | 6.555 (p:0.002) |
Brachial AIx: Brachial Augmentation index; Aortic Aix: Aortic Augmentation index; PWV: Pulse Wave Velocity; AVR: arteriole-to-venule ratio. Mean ± S: Mean ± Standard Deviation.
Retinal artery diameter, retinal vein diameter and AVR in Essential Hypertension and Primary Aldosteronism: analysis of variance and influence of the covariates: age, systolic blood pressure, eGFR and pulse pressure.
| ANOVA (F ratio, p value) | ANCOVA (F ratio, p value) | ||||
|---|---|---|---|---|---|
| Age (years) | Systolic Blood Pressure (mmHg) | eGFR (ml/min) | Pulse Pressure (mmHg) | ||
|
| 0.0997 (p:0.905) | 1.61 (p:0.19) | 2.85 (p:0.07) | 1.58 (p:0.19) | 2.87 (p: 0.08) |
| PA vs Control | p: 0.061 | p:0.43 | p:1.00 | p:0.23 | p:0.45 |
| PA vs EH | p:0.126 | p:0.10 | p:0.77 | p:0.47 | p:0.70 |
| EH vs control | p:0.476 | p:1.00 | p:1.00 | p:1.00 | p:1.00 |
|
| 2.02 (p: 0.11) | 2.02 (p: 0.11) | 2.37 (p:0.07) | 2.00 (p: 0.11) | |
| PA vs Control | p: 0.04 | p:0.12 | p:0.17 | p:1.00 | p:0.13 |
| PA vs EH | p: 0.017 | p:0.08 | p:0.08 | p:0.72 | p:0.08 |
| EH vs control | p: 0.96 | p:1.00 | p:1.00 | p:0.58 | p:1.00 |
|
| 4.72 (p:0.004) | 4.33 (p:0.006) | 5.32 (p:0.002) | 4.34 (p:0.006) | |
| PA vs Control | p: 0.001 | p:0.001 | p:0.006 | p:0.0007 | p: 0.003 |
| PA vs EH | p: 0.021 | p:0.061 | p:0.056 | p:0.015 | p:0.06 |
| EH vs control | p: 0.194 | p:0.42 | p:0.60 | p:0.15 | p:0.61 |
PA: primary aldosteronism. EH: essential hypertension. AVR: arteriole-to-venule ratio. eGFR: estimated glomerular filtration rate.
Figure 1Example of an image obtained by retinal vessel analyzer (RVA) and then processed by Imedos software that provided the caliber of the vessels emerging from the optic disc. The assessments of the arterial calibre and of the vein calibre were taken between 1 and 2 disc diameters from the margin of the optic disc, in correspondence with the major superior temporal arteries (Red Arrow) and vein (Blue Arrow) of the right eye.